ライフサイエンスコーパス: IL-2 receptor

1 L-2) that targets tumor cells expressing the IL-2 receptor.

2 ted lymphocytes expressing the high-affinity IL-2 receptor.

3 lymphocytes depends on signaling through the IL-2 receptor.

4 mechanism that blocks signaling through the IL-2 receptor.

5 e at concentrations equal to the K(D) of the IL-2 receptor.

6 ithout affecting their surface expression of IL-2 receptor.

7 sponses despite strong signaling through the IL-2 receptor.

8 urface expression of CD25, the high-affinity IL-2 receptor.

9 sents the high-affinity alpha-subunit of the IL-2 receptor.

10 terleukin-2 (IL-2) via ectopically expressed IL-2 receptors.

11 usly expressed cytokine receptors, including IL-2 receptors.

12 signals emanating from exogenously expressed IL-2 receptors.

13 n is an essential component of high-affinity IL-2 receptors.

14 equent decreased gene expression of IL-2 and IL-2 receptors.

15 okine to cells expressing different kinds of IL-2 receptors.

16 common gamma-chain functional high-affinity IL-2 receptors.

17 ting T cell functions through interleukin-2 (IL-2) receptors.

18 antigen 4 (CTLA4), interleukin (IL)-2/IL-21, IL-2 receptor A (IL-2RA; CD25) and Eos (also known as Ik

19 Daclizumab is a humanized mAb that binds the IL-2 receptor a subunit (IL-2R a or CD25) and prevents I

20 the alloantigen Thy-1 (CD90), interleukin 2 (IL-2) receptor a-chain (CD25), IL-7 receptor a-chain (CD

21 Blocking the common gamma c of IL-2 receptor, a shared essential signaling component by

22 These results demonstrate that the IL-2 receptor activation, among other early events, lead

23 observed an impaired IFNgamma production on IL-2 receptor activation.

24 ermore, PGE2 downregulated the expression of IL-2 receptor alpha (CD25).

25 ed a child born with a genetic deficiency of IL-2 receptor alpha (IL-2Ralpha, CD25) expression who ha

26 Ab)-mediated inhibition of the high-affinity IL-2 receptor alpha (IL-2Ralpha/CD25) during immunothera

27 a), interleukin 3 (IL-3), IL-4, IL-5, IL-13, IL-2 receptor alpha (IL-2Ralpha; CD25), CD40L, and macro

28 eas STAT5 phosphorylation and DNA binding to IL-2 receptor alpha (IL2RA) are reduced or not affected

29 ow that an MS-associated polymorphism in the IL-2 receptor alpha (IL2RA) gene specifically increases

30 d IPEX-like disorders caused by mutations in IL-2 receptor alpha (IL2RA), signal transducer and activ

31 Elevated serum levels of the soluble form of IL-2 receptor alpha (sIL-2Ralpha) have been correlated w

32 d from that of the antibody by using an anti-IL-2 receptor alpha antibody single chain Fv-streptavidi

33 s) are characterized by a high expression of IL-2 receptor alpha chain (CD25) and of forkhead box P3

34 Interleukin 2 (IL-2) signaling through the IL-2 receptor alpha chain (CD25) facilitates HIV replica

35 n of these cells is associated with impaired IL-2 receptor alpha chain (CD25) gene and cell surface e

36 ppressed the expression of the high affinity IL-2 receptor alpha chain (CD25) on virus-specific CD4 T

37 rotein A repetitions predominant (GARP), the IL-2 receptor alpha chain (CD25), and programmed cell de

38 xpression on CD8(+) T cells of high-affinity IL-2 receptor alpha chain (CD25), costimulatory molecule

39 IL-12 stimulated increases in IL-2 receptor alpha chain gene (CD25) mRNA levels and su

40 CD8(+) T cells can account for the impaired IL-2 receptor alpha chain gene expression.

41 age colony-stimulating factor (GM-CSF ), and IL-2 receptor alpha chain gene.

42 Serum soluble IL-2 receptor alpha chain levels and in vitro immunoglob

43 ductions in interleukin (IL)-2 secretion and IL-2 receptor alpha chain mRNA transcription, suggesting

44 egulated programmed death-1 (PD-1) and CD25 (IL-2 receptor alpha chain), and led to antigen-specific

45 s of immune dysregulation, including soluble IL-2 receptor alpha chain, CD45RO(+)CD4(+) effector T ce

46 ransduced cells had higher expression of the IL-2 receptor alpha chain, DN Ikaros-transduced cells ac

47 ptide corresponding to residues 61-73 of the IL-2 receptor alpha chain.

48 tional expression of CD25, the high affinity IL-2 receptor alpha chain.

49 ient in interleukin (IL)-2 production or the IL-2 receptor alpha or beta chains develop a lethal auto

50 find a reduced pH sensitivity of binding to IL-2 receptor alpha relative to IL-2 receptor beta compa

51 The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal a

52 he anti-human Tac monoclonal antibody to the IL-2 receptor alpha subunit fused to a 38-kDa fragment o

53 We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for s

54 the most informative biomarkers, followed by IL-2 receptor alpha, alpha1-antitrypsin, C-reactive prot

55 2) inhibitor, NS398, significantly increased IL-2 receptor alpha-chain (CD25) expression on phytohema

56 ls of CD44 (CD44high) and high levels of the IL-2 receptor alpha-chain (CD25high).

57 at express CD56 and CD3 antigen, and soluble IL-2 receptor alpha-chain (sIL-2R alpha) levels before t

58 ic construct consisting of the extracellular IL-2 receptor alpha-chain and the cytoplasmic ADAM15 dom

59 e entire Ag-specific population up-regulated IL-2 receptor alpha-chain expression, underwent blast tr

60 , but the peak of expression occurred before IL-2 receptor alpha-chain up-regulation, and only a mino

61 ency of naive CD4 T cells that express CD25 (IL-2 receptor alpha-chain) increases with age on subsets

62 cing membrane and soluble forms of CD25, the IL-2 receptor alpha-chain, and quenching T-cell-derived

63 in 15- to 30-fold increased affinity for the IL-2 receptor alpha-subunit (IL-2Ralpha).

64 d loop involving increased expression of the IL-2 receptor alpha-subunit and activation of the transc

65 es that express IL-15 receptor alpha but not IL-2 receptor alpha.

66 receptor beta/gamma heterodimer (but not the IL-2 receptor alpha/beta/gamma complex) have the potenti

67 (+) T cells down-regulate the interleukin 2 (IL-2) receptor alpha (IL2RA, or CD25) protein and show s

68 rface expression of the human interleukin-2 (IL-2) receptor alpha (IL2RA, or CD25) protein are restri

69 CD25, the high-affinity interleukin-2 (IL-2) receptor alpha chain, is rapidly upregulated by an

70 Interleukin-2 (IL-2) receptor alpha knockout (IL-2Ralpha(-/-)) mice hav

71 to reduced expression of the interleukin-2 (IL-2) receptor alpha subunit CD25, accumulation of Foxp3

72 ely express the high-affinity interleukin 2 (IL-2) receptor alpha-chain (CD25); however, the precise

73 D69 but not the high-affinity interleukin 2 (IL-2) receptor alpha-chain CD25 and produce gamma interf

74 ct in the expression of CD25 (interleukin-2 [IL-2] receptor alpha chain) on Ad5-elicited CD4 T cells,

75 n, the latter by promoting endocytic loss of IL-2 receptor-alpha (CD25).

76 n of CD56+CD3- cells and an up-regulation of IL-2 receptor-alpha expression on natural killer cells.

77 determined the prognostic relevance of CD25 (IL-2 receptor-alpha) expression in 657 patients (</= 60

78 sly validated diagnostic biomarkers of GVHD (IL-2 receptor-alpha; tumor necrosis factor receptor-1; h

79 h significantly increased serum interleukin (IL)-2 receptor and IL-12 levels, which is consistent wit

80 oliferation by enhancing signals through the IL-2 receptor and by other mechanisms independent of the

81 hanism of inhibition involved suppression of IL-2 receptor and Jak3 expression.

82 y these migrants sustained expression of the IL-2 receptor and promoted delayed type hypersensitivity

83 tial stages of G1, including upregulation of IL-2 receptor and synthesis of IL-2.

84 ary, costimulation of human NK cells via the IL-2 receptor and the IL-12 receptor induces significant

85 ylation of STAT3 and STAT5 downstream of the IL-2 receptor and upregulation of T-bet expression.

86 Antibodies against the gamma chain of the IL-2 receptor and, to a lesser extent, against the beta

87 8(+)CD18(bright) T cells expressed IL-12 and IL-2 receptors and adhesion/costimulatory molecules to a

88 (IL-2Ralpha) is a component of high affinity IL-2 receptors and thus critically regulates T cell grow

89 alpha) chain is a component of high-affinity IL-2 receptors and thus is a key regulator of lymphocyte

90 fies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytoki

91 with the common chain of the interleukin-2 (IL-2) receptor and is involved in the function of the re

92 ight deficiencies in both the interleukin-2 (IL-2) receptor and its downstream signaling pathway as a

93 y expresses the high-affinity interleukin 2 (IL-2) receptor and produces immunoregulatory cytokines.

94 inflammatory markers (eg, ferritin, soluble IL-2 receptor) and T cells and monocytes activation (ie,

95 ndent upon TCR engagement with MHC class II, IL-2 receptor, and Akt signaling, but not upon costimula

96 e increased expression of the interleukin-2 (IL-2) receptor, and combination with the IL-2 toxin conj

97 e compared with those receiving interleukin (IL)-2-receptor antagonists (n=217) or antithymocyte glob

98 ilar in patients induced with alemtuzumab or IL-2 receptor antagonists.

99 and repeated after the addition of the anti-IL-2 receptor (anti-CD25) monoclonal antibody, basilixim

100 (group 3; n = 43); and CITR recipients given IL-2 receptor antibodies (IL-2RAb) alone (group 4; n = 1

101 splantation and the use of anti-interleukin (IL)-2 receptor antibody as a maintenance immunosuppressa

102 yte, polyclonal antilymphocyte, interleukin (IL)-2 receptor antibody, or no induction therapy in prim

103 immunosuppressive therapy using interleukin (IL)-2 receptor antibody, tacrolimus, mycophenolate mofet

104 Determine the impact of cytolytic versus IL-2 receptor antibody (IL-2RA) induction on acute rejec

105 Use of anti-IL-2 receptor antibody as a part of maintenance immunosu

106 The addition of humanized IL-2 receptor antibody daclizumab (DZB) to CsA-based imm

107 olate mofetil (MMF), sirolimus, and the anti-IL-2 receptor antibody daclizumab consistently resulted

108 Among induction therapies, IL-2 receptor antibody induction was associated with the

109 cells was performed with injections of anti-IL-2 receptor antibody into the mice.

110 ptor, conferred cell-spreading capability on IL-2 receptor antibody substrates.

111 Anti-IL-2 receptor antibody therapy, given intravenously with

112 e in AR from 75% to 44% with the use of anti-IL-2 receptor antibody therapy.

113 From 2008 onwards (second era), monthly anti-IL-2 receptor antibody was added to the maintenance immu

114 IL-2 receptor antibody was associated with a 17% reduced

115 signaling by calcineurin inhibition or anti-IL-2 receptor-antibody blockade.

116 zation kinetics of 2D1 via the high affinity IL-2 receptor are equivalent to those of WT but that a s

117 Dysregulation of the IL-2-IL-2 receptor axis is associated with aberrant Foxp3(+)T

118 that diverge in response to signals from the IL-2 receptor, Bcl6, and B cells.

119 cosal EG2+ (activated eosinophils) or CD25+ (IL-2-receptor-bearing) cells, nor did they decrease the

120 lineage conversion in CLPs are delivered via IL-2 receptor beta (IL-2R beta) intracellular domains.

121 mple, Jak1 and Jak3 bind specifically to the IL-2 receptor beta (IL-2Rbeta) and common gamma (gammac)

122 n-2 (IL-2) induces heterodimerization of the IL-2 receptor beta (IL-2Rbeta) and gammac chains of its

123 ransfected with the cDNA for the full-length IL-2 receptor beta (IL-2Rbeta) and gammac chains, compon

124 ntroducing wild-type and mutant forms of the IL-2 receptor beta (IL-2Rbeta) chain that lacked specifi

125 growth by exogenous IL-2, which binds to the IL-2 receptor beta (IL-2Rbeta) chain ubiquitously expres

126 -8), monocyte chemotactic protein 3 (MCP-3), IL-2 receptor beta (IL-2Rbeta), IL-15 receptor alpha (IL

127 Common to both cytokine receptors, the IL-2 receptor beta (IL2Rbeta) chain is selectively maint

128 E5 in transformation, as well as bind to the IL-2 receptor beta and gamma chains and the H+ vacuolar

129 e find that IL-2C targeting cells expressing IL-2 receptor beta cause an acute decrease in cellularit

130 receptor (NILR), that is most related to the IL-2 receptor beta chain (IL-2Rbeta) and physically adja

131 now have found that tyrosine residues in the IL-2 receptor beta chain (IL-2Rbeta) are unexpectedly no

132 n of intracellular substrates, including the IL-2 receptor beta chain (IL-2Rbeta), Janus kinase 1 (Ja

133 ) receptor beta common chain (betac) and the IL-2 receptor beta chain (IL-2Rbeta), lack such sites, l

134 ly explained by diminished expression of the IL-2 receptor beta chain (IL-2Rbeta), which is a compone

135 demonstrate that CIS also interacts with the IL-2 receptor beta chain (IL-2Rbeta).

136 ion was markedly enhanced by the presence of IL-2 receptor beta chain (IL-2Rbeta).

137 receptor (IL-21R) is closely related to the IL-2 receptor beta chain and is capable of transducing s

138 h an activated phenotype, phenotypes seen in IL-2 receptor beta chain-deficient mice.

139 s largely dependent upon tyrosine 338 of the IL-2 receptor beta chain.

140 f binding to IL-2 receptor alpha relative to IL-2 receptor beta compared with WT, which could be resp

141 The IL-2 receptor beta subunit (IL-2Rbeta) serves in this ca

142 ng specificity for IL-2 or IL-15, and shared IL-2 receptor beta- and gamma-chains.

143 the common gamma chain (gammac) and through IL-2 receptor beta-chain (CD122) subunits, they direct d

144 The interleukin-2 IL-2 receptor beta-chain (IL-2Rbeta) is an essential com

145 T cells by their expression of the signaling IL-2 receptor beta-chain CD122, forming with common gamm

146 How the IL-2 receptor beta-chain specifically shapes immunity ha

147 pression of cell surface receptors including IL-2 receptor beta.

148 nant interleukin engineered to stimulate the IL-2 receptor beta/gamma heterodimer (but not the IL-2 r

149 Its interaction with the interleukin-2 (IL-2) receptor beta- and gamma-chains implies an involve

150 r of Il2rb, which encodes the interleukin 2 (IL-2) receptor beta-chain, and controlled the responsive

151 ent spleens, mRNAs were low for interleukin (IL)-2 receptor-beta, interferon regulatory factor-1, and

152 NKTR-214 is a kinetically-engineered IL-2 receptor betagamma (IL-2Rbetagamma)-biased agonist

153 tokine interleukin-2 (IL-2) that bind to the IL-2 receptor betagamma(c) heterodimer (IL-2Rbetagamma(c

154 at compounds bound reversibly to IL-2 at the IL-2 receptor binding site.

155 teroids in individuals with severe AH and if IL-2 receptor blockade can reverse this.

156 IL-2 receptor blockade represents a possible mechanism t

157 IL-2-receptor blockade is effective for preventing allor

158 idence interval [CI] 1.10-1.43, P=0.001) and IL-2 receptor blocker (n=1396, HR 1.19, 95% CI 1.01-1.39

159 When compared with alemtuzumab and IL-2 receptor blocker, r-ATG induction seems to be assoc

160 n (r-ATG), alemtuzumab, or an interleukin-2 (IL-2) receptor blocker and were discharged on a calcineu

161 Gene expression of IL-2 and IL-2 receptors (both alpha and beta) and binding of NF-k

162 system that does not share elements with the IL-2 receptor but uses a novel 60- to 65-kDa IL-15RX sub

163 cancer was shown to express the interleukin (IL)-2 receptor by an immunohistochemical assay for the p

164 ation of the IL-2 pathway with a bias to the IL-2 receptor CD122 (IL-2Rbeta).

165 oantigen-specific T suppressor cells express IL-2 receptor (CD25) and that IL-2 in part promotes thei

166 th decreased expression of the high affinity IL-2 receptor (CD25).

167 erapy using the chimeric anti-interleukin-2 (IL-2) receptor (CD25) monoclonal antibody (mAb) basilixi

168 ferences between cell lines were observed in IL-2 receptor chain (alpha, beta, or gamma(c)) expressio

169 ing was performed to study expression of the IL-2 receptor chains on T lymphocytes and natural killer

170 The response is induced via IL-2 receptor common gamma chain cytokines and a Janus k

171 t allowed for coexpression of MDR1 and human IL-2 receptor common gamma-chain cDNAs.

172 r) kinase associated with the interleukin-2 (IL-2) receptor common gamma chain (gamma(c)) that is act

173 of a targeted mutation in the interleukin 2 (IL-2) receptor common gamma chain (IL2rg(null)) into mic

174 -gamma or genetic deletion of interleukin 2 (IL-2) receptor common gamma chain in Rag-deficient mice

175 three chains (CD25, CD122, and CD132) of the IL-2 receptor complex and are dependent on IL-2 for surv

176 cells, SOCS-3 was able to interact with the IL-2 receptor complex, and in particular tyrosine phosph

177 t IL-2 induces association of SHP-1 with the IL-2 receptor complex, and that once SHP-1 is recruited

178 ent of the tyrosine phosphatase TCPTP to the IL-2 receptor complex, which resulted in dephosphorylati

179 rum levels of the soluble alpha chain of the IL-2 receptor complex.

180 ignaling by IL-4, IL-7, and IL-15, which use IL-2 receptor components, also was inhibited, indicating

181 2 did not result in dephosphorylation of the IL-2 receptor components.

182 usion of the cytosolic domain of TEM8 to the IL-2 receptor, conferred cell-spreading capability on IL

183 ed IL-2, acting through the NK high-affinity IL-2 receptor, costimulates CD56(bright) NK cells to sec

184 y in which T cells lacking the high-affinity IL-2 receptor could be studied in an otherwise healthy m

185 onoclonal antibody against the high-affinity IL-2 receptor (daclizumab) was performed in 70 adult, ca

186 The use of IL-2- or IL-2-receptor-deficient mice is problematic owing to the

187 oduced Th1 memory cells in an interleukin-2 (IL-2) receptor-dependent fashion.

188 bodies that recognize the alpha chain of the IL-2 receptor (e.g. daclizumab) have been used to preven

189 ucture of the trimeric assembly of the human IL-2 receptor ectodomains in complex with IL-2 at 3.0 A

190 r blockade of the high-affinity interleukin (IL)-2 receptor effectively prevented T-cell alloreactivi

191 noclonal antibody against the interleukin 2 (IL-2) receptor expressed on activated T lymphocytes.

192 in showed antitumor effects in patients with IL-2 receptor expressing CTCL and NHL.

193 We have previously shown that interleukin (IL)-2 receptor-expressing lymphoid cells stimulated with

194 -2]), a recombinant fusion protein targeting IL-2 receptor-expressing malignant T lymphocytes, in pat

195 the CD70(+)CD8(+) T cells that up-regulated IL-2 receptor expression but did not occur in CD70(-)CD8

196 y IL-2 in G(1) with no appreciable effect on IL-2 receptor expression in a manner similar to that of

197 es, rhIL-2 increased viral protein (p24) and IL-2 receptor expression in isolated B lymphocytes from

198 T cell proliferation associated with reduced IL-2 receptor expression, but operating independently of

199 Loss of interleukin-7 (IL-2) receptor expression has been described in T lympho

200 In this study, we tested interleukin-2 (IL-2) receptor expression, IL-2-mediated proliferation,

201 t containing the non-adhesive interleukin-2 (IL-2) receptor extracellular domain and the VE-cadherin

202 racellular domains of the Tac subunit of the IL-2 receptor, fused to the cytoplasmic domain of beta(1

203 ptor alpha (IL-4Ralpha)-chain but not to the IL-2 receptor gamma (IL-2Rgamma)-chain.

204 mutations in IL-7 receptor alpha (IL7RA) and IL-2 receptor gamma (IL2RG) were observed at the most im

205 recombination activating gene 1/2 (RAG 1/2), IL-2 receptor gamma (IL2RG), and zeta chain-associated p

206 kins 9 (IL-9) and 4 are cytokines within the IL-2 receptor gamma chain (IL-2R gamma) superfamily that

207 seen in immunodeficient patients lacking the IL-2 receptor gamma chain or Jak3.

208 afted at a markedly higher level in NOD/SCID/IL-2 receptor gamma chain-null (NSG) mice compared with

209 The IL-2 receptor gamma common (IL-2Rgammac) chain is the sh

210 s, patients with the p.R222C mutation in the IL-2 receptor gamma(IL2RG) gene as well as IL-10 recepto

211 cells in NOD-SCID gamma (with interleukin-2 (IL-2) receptor gamma chain deficiency) mice also reveale

212 intestinal compartment in humanized NOD/SCID/IL-2 receptor-gamma(null) (NSG) mice.

213 l growth factors (TCGFs), utilize the common IL-2 receptor gammac chain as a critical signaling compo

214 The IL-10 receptor and the IL-2 receptor gammac chain were almost equally expressed

215 hanisms for the recruitment of PI 3-K to the IL-2 receptor have been proposed.

216 -cadherin tail was fused to the interleukin (IL)-2 receptor (IL-2R) extracellular domain.

217 IV-1) replication in activated, interleukin (IL)-2 receptor (IL-2R)-expressing human peripheral blood

218 r the contribution of the interleukin (IL)-2/IL-2 receptor (IL-2R) autocrine pathway.

219 lymphoma cells expressing the high-affinity IL-2 receptor (IL-2R) consisting of the alpha/p55/CD25,

220 together comprise the intermediate affinity IL-2 receptor (IL-2R) expressed on the surface of restin

221 ival mechanisms, none of the 3 chains of the IL-2 receptor (IL-2R) expresses a binding site for PI 3-

222 The IL-2 receptor (IL-2R) is composed of IL-2Ralpha, IL-2Rbe

223 ed accumulation of T cell receptor (TCR) and IL-2 receptor (IL-2R) mediated signaling events that pro

224 ns, multiple genes in the interleukin (IL)-2/IL-2 receptor (IL-2R) pathway are associated with type 1

225 ct, exhibited significantly higher levels of IL-2 receptor (IL-2R) signaling compared with those in l

226 f transcription (STAT)5, which are linked to IL-2 receptor (IL-2R) signaling pathway, were not affect

227 ell as proliferation, making unclear whether IL-2 receptor (IL-2R) signals ultimately have a predomin

228 f altered interleukin-2 (IL-2) secretion and IL-2 receptor (IL-2R)-signal transducer and activator of

229 60 nM inhibitor of the interleukin-2 (IL-2)/IL-2 receptor (IL-2Ralpha) interaction.

230 ors, which share the common gamma chain with IL-2 receptors, IL-7 cannot initiate lineage conversion

231 The gene encoding the alpha-chain of the IL-2 receptor, IL2RA, harbors alleles associated with ri

232 ate with the levels of a soluble form of the IL-2 receptor in subjects with type 1 diabetes and multi

233 We previously showed that the IL-2 receptor induces expression of cyclin D2 by activat

234 htheria toxin and ligand, IL-2, binds to the IL-2 receptor, is internalized, and causes cell death.

235 on IL-2 activity in that it was not seen in IL-2 receptor knockout mice, while PspA in alum induced

236 he IL-2 molecule alter interactions with the IL-2 receptor, leading to differential cellular targetin

237 ted a clear correlation between interleukin (IL) 2 receptor levels and immunological events after tra

238 ase elevation correlated with plasma soluble IL-2 receptor levels and not with viremia levels.

239 correlates including ch14.18 levels, soluble IL-2 receptor levels, and human antichimeric antibody (H

240 ntial therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in the treatment

241 CsA and anti-IL-2 receptor mAb are drugs that reduce cytokine synthes

242 This is the first study to combine an anti-IL-2 receptor mAb with a drug from the rapamycin class p

243 monoclonal antibody (mAb) basiliximab (anti-IL-2 receptor mAb) for induction therapy (basiliximab: 5

244 (e.g., IL-15) that are not inhibited by anti-IL-2 receptor mAb.

245 Introduction of Pax5 blocks ectopic IL-2 receptor-mediated myeloid lineage conversion in CLP

246 ults indicate that TCR-CD3/CD28-mediated and IL-2 receptor-mediated signals converge at the level of

247 orylation plays a key role in interleukin-2 (IL-2) receptor-mediated activation of Janus tyrosine kin

248 eg cells the expression of the high-affinity IL-2 receptor, needed for STAT5-dependent survival of Tr

249 we sought to dissect the effects of CD28 and IL-2 receptor pathways on cell cycle progression and det

250 The interleukin-2 (IL-2) receptor promotes T cell proliferation in part by

251 r, to be crucially regulated by interleukin (IL)-2 receptor (R) signals.

252 temporal expression of the cytokine-specific IL-2 receptor (R) alpha and IL-7Ralpha chains.

253 the beta and common gamma(c) subunits of the IL-2 receptor (R) as a heterodimer with intermediate aff

254 2 secretion and subsequent signaling via the IL-2 receptor, recent studies indicate that the dramatic

255 Therapeutic immune modulation of IL-2 receptor restores impaired immune regulation in MS

256 Analysis of mutants of the beta-chain of the IL-2 receptor revealed that the granulocyte- and monocyt

257 ets the STAT5 signaling pathway to attenuate IL-2 receptor signal transduction in human T cells.

258 IV gp120-derivatives attenuates interleukin (IL)-2 receptor signaling.

259 We demonstrate that CARMA1 regulates IL-2 receptor signaling and controls the IL-2-stimulated

260 ly redundant pathways exist for formation of IL-2 receptor signaling complexes, suggesting a more com

261 c memory cells which is primarily favored by IL-2 receptor signaling during ex vivo generation of the

262 Consistent with this, sustained IL-2 receptor signaling during expansion drove terminal-

263 m lymphoid to myeloid in response to ectopic IL-2 receptor signaling in human IL-2Rbeta transgenic mi

264 tion of IFNgamma, in addition to a defective IL-2 receptor signaling machinery and a defective commun

265 In addition, timely blockade of IL-2 receptor signaling selectively inhibits the product

266 ires TCR-induced early GATA-3 expression and IL-2 receptor signaling, both of which are controlled by

267 cytoskeleton, resulting in amplification of IL-2 receptor signaling, enhanced CD122/CD132 colocaliza

268 ted IL-2-induced proliferation by uncoupling IL-2 receptor signaling, inhibiting phosphorylation of t

269 that rapamycin (RAPA), a drug that disrupts IL-2 receptor signaling, reduces CCR5 surface expression

270 ation involves both NF-kappaB activation and IL-2 receptor signaling.

271 , confirming PTEN as a negative regulator of IL-2 receptor signaling.

272 ven TCR signals combined with interleukin 2 (IL-2) receptor signalling.

273 reatment were analyzed for levels of soluble IL-2 receptor (sIL-2R).

274 , IL-6 (p = .073), IL-10 (p = .013), soluble IL-2 receptor (sIL-2R; p < .001), sIL-6R (p = .021), tum

275 Levels of soluble IL-2 receptors (sIL-2R) are elevated in psychiatric diso

276 aying binding affinity to the heterotrimeric IL-2 receptor similar to that of wild-type IL-2 (WT) had

277 tokine surface receptors, IL-9R alpha-chain, IL-2 receptor ss-chain, and erythropoietin receptor, can

278 s is explained by their higher expression of IL-2 receptor subunit alpha (IL-2Ralpha) and gamma chain

279 To address this, we created 2 NOD- scid IL-2 receptor subunit gamma ( IL2rg) (null) (NSG) strain

280 ice and mice lacking the beta-subunit of the IL-2 receptor suggest that there is an unexpected connec

281 ted with blocking antibodies to IL-2 and the IL-2 receptor, suggesting a possible BCL6-STAT5 binding

282 These insights concerning the IL-2/IL-2 receptor system facilitated the development of effe

283 eveal a previously unknown mechanism for the IL-2 receptor system in DC-mediated activation of T cell

284 Here, we mainly focus on the IL2-/IL-2 receptor system, as it is one of the best-studied s

285 several methods, including their binding to IL-2 receptors, T-cell proliferation assays, the inducti

286 tant negative regulator of signaling via the IL-2 receptor that affects the development of Treg cells

287 inhibits up-regulation of the high-affinity IL-2 receptor that is necessary for T(CD8) survival.

288 cytokines including CCL5, G-CSF, and soluble IL-2 receptor, that were significantly elevated in WM pa

289 of one of the two signalling subunits of the IL-2 receptor, the beta chain (CD122) (mean decrease = 5

290 ese initial findings would suggest that anti-IL-2 receptor therapy may be an effective therapeutic ap

291 on gamma (gamma(c)) chain heterodimer of the IL-2 receptor through trans-presentation by cells expres

292 tion of Gab2 may be important in linking the IL-2 receptor to activation of MAPK and may be an import

293 ta revealed that Janus kinases (JAKs) couple IL-2 receptors to the coordinated phosphorylation of tra

294 pression of the beta and gamma chains of the IL-2 receptor was detected in the IL-2 group.

295 that of IL-2 when the intermediate-affinity IL-2 receptor was expressed.

296 (+) T cell model using wild-type and mutated IL-2 receptors, we examined the effects of TGF-beta on d

297 gamma-inducible alpha subunit of the soluble IL-2 receptor were elevated in serum and bronchoalveolar

298 [TNF]-alpha, interleukin [IL]-6 and soluble IL-2 receptor) were investigated.

299 tion leads to the formation of high affinity IL-2 receptors when IL-2Ralpha is co-expressed with the

300 ng selective saturation of the high affinity IL-2 receptor, while the peak SCF serum concentration wa